Asthma Therapeutics  Market, by Drug Class (Corticosteroids, Beta2-Agonists (Long-acting and Short-acting), Leukotriene Inhibitors, Long-acting Muscarinic Antagonists (LAMA), Interleukin Antagonists, Anti-immunoglobulin E (IgE) Agents, Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids, and Others), and Others), by Route of Administration (Oral, Inhalation, and Injection), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Jun 2019 |
  • Pages : 157 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Asthma Therapeutics Market Insights

Asthma is a type of chronic respiratory disease, which is characterized by attacks of breathlessness and wheezing. Asthma can occur at any stage, though it is the most common disease in children. Asthma attacks are linked to respiratory infections and environmental factors such as allergens, tobacco, smoke, and indoor and outdoor pollution. Indoor pollution factors include mold, chemicals, strong odors, and house dust whereas outdoor pollution factors include air pollution, allergens, tobacco, and smoking. Such factors are responsible for development and exacerbation of asthma.

The global asthma therapeutics market was valued at US$ 17,582.2 million in 2018, and is expected to witness a CAGR of 1.9% during the forecast period (2018 – 2026).

Figure 1. Global Asthma Therapeutics Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)

Asthma Therapeutics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Rise in number of respiratory disease cases is expected to drive growth of the global asthma therapeutics market.

Increasing prevalence of respiratory diseases is expected to drive global asthma therapeutics market growth. For instance, according to the World Health Organization’s (WHO) report 2016, around 235 million people suffer from asthma worldwide, annually. Asthma is a progressive and chronic life-threatening respiratory disease. Hence, increasing number of respiratory disease cases support the global asthma therapeutics market growth.

Moreover, increasing awareness activities are contributing to the global asthma therapeutics market growth. For instance, in May 2019, Koninklijke Philips N.V., launched campaign to increase awareness of asthma and related respiratory diseases, especially in children. This campaign was titled as ‘Help Your Child Fight against Asthma’.

Furthermore, product recall is the major restraining factor which is expected to hamper the growth of asthma therapeutics market. For instance, in August 2018, Camber Pharmaceuticals received product recall letter from U.S. Food and Drug Administration (USFDA) for its Montelukast Sodium Tablets. These tablets are recalled because. Montelukast Tablet bottles labeled as Montelukast Sodium Tablet but it contains Losartan Potassium Tablets.

Global Asthma Therapeutics Market- Regional Analysis

North America asthma therapeutics market is expected to account for the largest market share during the forecast period, owing to increasing number of product approvals by regulatory authorities in this region. For instance, in September 2018, U.S. Food and Drug Administration (FDA) announced approval of new Xolair (containing-Omalizumab) prefilled syringe formulation, for treatment of allergic asthma. Xolair is manufactured by Novartis AG.

Moreover, increasing regulatory approvals of new drug for treatment of asthma is expected to boost forecast value of asthma therapeutics market in this region. For instance, in October 2018, U.S. Food and Drug Administration (USFDA) announced approval of new drug Dupixent (contains- Dupilumab), developed by the Regeneron Pharmaceuticals, for the treatment and prevention of pulmonary/respiratory diseases including moderate-to-severe asthma.

Furthermore, Asia Pacific is expected to hold significant market share in the asthma global therapeutics market over the forecast period, owing to increasing product launches by key players in this region. For instance, in April 2019, Cipla announced launch of its new inhaler Niveoli in India. It is India’s first extra-fine particle Beclomethasone-formoterol combination Hydrofluoroalkane (HFA) inhaler for adults. It is indicated for the treatment of obstructive airways diseases (OAD) such as asthma and Chronic Obstructive Pulmonary Disease (COPD).hence increasing number of product launches will support the growth of asthma therapeutics market.

Figure 2: Global Asthma Therapeutics Market Value (US$ Mn), By Region

Asthma Therapeutics  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Global Asthma Therapeutics Market - Competitive Landscape

Key players operating in the asthma therapeutics market include GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.

Asthma is a long-term inflammatory disease that causes inflammation and narrowing of the airways in the lung. It is characterized by various symptoms such as swelling or inflammation in the airways linings, coughing, shortness of breath, and tightness of chest. Asthma is classified into many different types including allergic asthma, non-allergic asthma, adult onset asthma, exercised induced asthma (that occurs with physical exertion), nocturnal asthma, and occupational asthma. Nocturnal is also known as the nighttime asthma. It is very serious type of asthma therefore, it needs a proper diagnosis and treatment.

Market Dynamics

Increasing launches of nebulizer by key players is expected to propel global asthma therapeutics market growth. For instance, in October 2018, Koninklijke Philips N.V. announced launch of its new mesh nebulizer, InnoSpire Go, in North America. This is used for the treatment of respiratory diseases including asthma. It is portable, hand-held nebulizer system, which is short time treatment. It delivers the medicine in just four minutes. InnoSpire Go designed for both adults and children.

However, product recall is major restraining factor for asthma therapeutics market growth, which is expected to hamper the market growth. For instance, in August 2018, Camber Pharmaceuticals were issued product recall alert from U.S. Food and Drug Administration for its Montelukast Sodium Tablets. These tablets are recalled because Montelukast Sodium Tablet bottles contain wrong medicine (Losartan Potassium Tablet).

Key features of the study:

  • This report provides in-depth analysis of the global asthma therapeutics market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global asthma therapeutics market based on the following parameters–company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global asthma therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for global asthma therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Asthma Therapeutics Market, By Drug Class:
    • Corticosteroids
    • Beta2-Agonists (Long-Acting and Short-Acting)
    • Leukotriene Inhibitors
    • Long-Acting Muscarinic Antagonists (LAMA)
    • Interleukin Antagonists
    • Anti-Immunoglobulin E (IgE) Agents
    • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
    • Others
  • Global Asthma Therapeutics By Route of Administration:
    • Oral
    • Inhalation
    • Injection
  • Global Asthma Therapeutics market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Asthma Therapeutics market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Class
        • Corticosteroids
        • Beta2-Agonists (Long-Acting and Short-Acting)
        • Leukotriene Inhibitors
        • Long-Acting Muscarinic Antagonists (LAMA)
        • Interleukin Antagonists
        • Anti-Immunoglobulin E (IgE) Agents
        • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Class
        • Corticosteroids
        • Beta2-Agonists (Long-Acting and Short-Acting)
        • Leukotriene Inhibitors
        • Long-Acting Muscarinic Antagonists (LAMA)
        • Interleukin Antagonists
        • Anti-Immunoglobulin E (IgE) Agents
        • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
        • Others
      • By Route of Administration:
        • Oral
        • Intravenous
        • Subcutaneous
      • By Distribution Channel:
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
        • By Country:
          • Australia
          • India
          • China
          • Japan
          • ASEAN
          • South Korea
          • Rest of Asia Pacific
        • By Drug Class
          • Corticosteroids
          • Beta2-Agonists (Long-Acting and Short-Acting)
          • Leukotriene Inhibitors
          • Long-Acting Muscarinic Antagonists (LAMA)
          • Interleukin Antagonists
          • Anti-Immunoglobulin E (IgE) Agents
          • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
          • Others
        • By Route of Administration:
          • Oral
          • Intravenous
          • Subcutaneous
        • By Distribution Channel:
          • Hospitals Pharmacies
          • Retail Pharmacies
          • Online Pharmacies
    • Latin America
        • By Country:
          • Brazil
          • Mexico
          • Argentina
          • Rest of Latin America
        • By Drug Class
          • Corticosteroids
          • Beta2-Agonists (Long-Acting and Short-Acting)
          • Leukotriene Inhibitors
          • Long-Acting Muscarinic Antagonists (LAMA)
          • Interleukin Antagonists
          • Anti-Immunoglobulin E (IgE) Agents
          • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
          • Others
        • By Route of Administration:
          • Oral
          • Intravenous
          • Subcutaneous
        • By Distribution Channel:
          • Hospitals Pharmacies
          • Retail Pharmacies
          • Online Pharmacies
    • Middle East
        • By Country:
          • GCC
          • Israel
          • Rest of Middle East
        • By Drug Class
          • Corticosteroids
          • Beta2-Agonists (Long-Acting and Short-Acting)
          • Leukotriene Inhibitors
          • Long-Acting Muscarinic Antagonists (LAMA)
          • Interleukin Antagonists
          • Anti-Immunoglobulin E (IgE) Agents
          • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
          • Others
        • By Route of Administration:
          • Oral
          • Intravenous
          • Subcutaneous
        • By Distribution Channel:
          • Hospitals Pharmacies
          • Retail Pharmacies
          • Online Pharmacies
    • Africa
        • By Country/Region:
          • South Africa
          • Central Africa
          • North Africa
        • By Drug Class
          • Corticosteroids
          • Beta2-Agonists (Long-Acting and Short-Acting)
          • Leukotriene Inhibitors
          • Long-Acting Muscarinic Antagonists (LAMA)
          • Interleukin Antagonists
          • Anti-Immunoglobulin E (IgE) Agents
          • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
          • Others
        • By Route of Administration:
          • Oral
          • Intravenous
          • Subcutaneous
        • By Distribution Channel:
          • Hospitals Pharmacies
          • Retail Pharmacies
          • Online Pharmacies
    • Company Profiles
      • GlaxoSmithKline Plc.,*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Philips Healthcare
      • AstraZeneca Plc.
      • Teva Pharmaceutical Industries Ltd.
      • Boehringer Ingelheim GmbH
      • Sanofi-Aventis SA
      • CareFusion Corporation
      • Sunovion Pharmaceuticals, Inc.
      • Merck & Co., Inc.
      • Roche Diagnostics.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  1. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  2. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Technology Advancements
    • Epidemiology
    • Product Recalls
    • Government Initiatives
    • Historical Overview
    • Merger and Acquisition
    • Regulatory and Reimbursement Scenario
    • PORTER’S Five Forces
    • PEST Analysis
  3. Global Asthma Therapeutics Market, By Drug Class, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Beta2-Agonists (Long-Acting and Short-Acting)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Leukotriene Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Long-Acting Muscarinic Antagonists (LAMA)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Interleukin Antagonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Anti-Immunoglobulin E (IgE) Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
  1. Global Asthma Therapeutics Market, By Route of Administration, 2018 – 2026, (US$ Million)
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Inhalation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million
  1. Global Asthma Therapeutics Market, By Distribution Chanel, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  1. Global Asthma Therapeutics Market, By Region, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast By Country, 2016 – 2026, (US$ Million)
        • US.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • UK.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channels, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channels, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  1. Competitive Landscape
  • Heat Map Analysis
  • Company Profiles
    • GlaxoSmithKline Plc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Philips Healthcare
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • AstraZeneca Plc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Boehringer Ingelheim GmbH
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Sanofi- Aventis SA
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • CareFusion Corporation
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Sunovion Pharmaceutical Ltd.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Merck & Co. Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Roche Diagnostics
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
  • Analyst Views
  1. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 23 market data tables and 19 figures on “Asthma Therapeutics Market” - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.